Braftovi + Erbitux ± Mektovi: Transforming the Oncology Landscape – Market Trends & Forecasts
Overview of the Braftovi + Erbitux ± Mektovi Combination Therapy The combination therapy of Braftovi (encorafenib), Erbitux (cetuximab), and optionally Mektovi (binimetinib) has become an important treatment option for specific cancer types, particularly metastatic colorectal cancer (mCRC) with the BRAFV600E mutation. This targeted approach uti